Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps

Dominique van Mil, Xavier G.L.V. Pouwels, Hiddo Lambers Heerspink, Ron T. Gansevoort*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

40 Downloads (Pure)


It is well known that the worldwide prevalence of chronic kidney disease (CKD) has risen to over 10% of the general population during the past decades. Patients with CKD are at increased risk of both kidney failure and cardiovascular disease (CVD), posing a substantial health challenge. Therefore, screening for CKD is warranted to identify and treat patients early to prevent progression and complications. In this issue of the Journal, Yeo and colleagues provide an updated systematic review of the cost-effectiveness of screening for CKD in the general adult population. They show that screening for CKD in high-risk populations is cost-effective and that there is limited evidence for screening the general population. It should be noted that most studies they discuss do not consider the benefit of screening to prevent CVD in addition to preventing kidney failure, the treatment effect of novel therapeutic agents such as SGLT2 inhibitors, and the possibility of screening in a home-based setting. These three aspects will likely improve the cost-effectiveness of CKD screening, making it feasible to move towards general population screening for CKD.
Original languageEnglish
Article numbersfad254
JournalClinical Kidney Journal
Issue number1
Early online date9 Dec 2023
Publication statusPublished - Jan 2024


Dive into the research topics of 'Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps'. Together they form a unique fingerprint.

Cite this